SCHEMBL15970490

SCHEMBL15970490

Cn1c(=O)c(O)c(C(=O)NC[C@@H]2C[C@H]2c2ccc(F)cc2)c2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.55
MEN1 O00255 5/20 0.55
RAB9A P51151 4/20 0.48
KDM4E B2RXH2 3/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPC1 O15118 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
NLRP3 Q96P20 1/20 0.44
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
GAA P10253 2/20 0.42
PPARG P37231 1/20 0.41
NCOA2 Q15596 1/20 0.41
RIPK1 Q13546 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15969421 1.00 KMT2A (0.55) KMT2AMEN1RAB9AKDM4ESMN1; SMN2
SCHEMBL15969485 0.75 MEN1 (0.64) KMT2AMEN1RAB9AKDM4ENPC1
SCHEMBL15970320 0.75 NPC1 (0.53) KMT2AMEN1RAB9AKDM4ESMN1; SMN2
SCHEMBL15970010 0.74 MEN1 (0.57) KMT2AMEN1RAB9AKDM4ENPC1
SCHEMBL15969686 0.74 KMT2A (0.57) KMT2AMEN1RAB9AKDM4ENPC1
SCHEMBL15970001 0.73 MEN1 (0.64) KMT2AMEN1RAB9AKDM4ENPC1
SCHEMBL14848310 0.72 MEN1 (0.60) KMT2AMEN1RAB9AKDM4ENPC1
SCHEMBL15969705 0.72 KMT2A (0.52) KMT2AMEN1RAB9AKDM4ESMN1; SMN2
SCHEMBL15978953 0.71 MEN1 (0.70) KMT2AMEN1RAB9AKDM4ENPC1
SCHEMBL15969725 0.71 MEN1 (0.58) KMT2AMEN1RAB9AKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760840-B1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP claimed
EP-2760840-B1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP disclosed
US-20150105376-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-04-16 US disclosed
US-8946430-B2 Quinolinone carboxamide inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2015-02-03 US disclosed
US-20140243314-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105376-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, PNLIP, LPL KMT2A 1068/4885MEN1 4291/4885RAB9A 2622/4885
US-20140243314-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, PNLIP, LPL KMT2A 1068/4885MEN1 4291/4885RAB9A 2622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.